Overcoming tumor heterogeneity by ex vivo arming of T cells using multiple bispecific antibodies

BACKGROUND: Tumorous heterogeneity is a hallmark of tumor evolution and cancer progression, being a longstanding challenge to targeted immunotherapy. Ex vivo armed T cells (EATs) using IgG-(L)-scFv bispecific antibodies (BsAbs) are potent tumor-specific cytotoxic effectors. To improve the anti-tumor...

Descripción completa

Detalles Bibliográficos
Autores principales: Park, Jeong A, Cheung, Nai-Kong V
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2022
Materias:
Immune Cell Therapies and Immune Cell Engineering
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8796264/
https://www.ncbi.nlm.nih.gov/pubmed/35086947
http://dx.doi.org/10.1136/jitc-2021-003771

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8796264/
https://www.ncbi.nlm.nih.gov/pubmed/35086947
http://dx.doi.org/10.1136/jitc-2021-003771

Ejemplares similares